Inovio Pharmaceuticals Stock Math Operators Price Series Division
| INO Stock | USD 1.68 -0.01 -0.59% |
| Symbols |
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Inovio Pharmaceuticals Price Series Division is a division of Inovio Pharmaceuticals price series and its benchmark/peer.
Inovio Pharmaceuticals Technical Analysis Modules
Most technical analysis of Inovio Pharmaceuticals help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Inovio from various momentum indicators to cycle indicators. When you analyze Inovio charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus , cancer, and infectious diseases. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania. Inovio Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 317 people. The stock overview for Inovio Pharmaceuticals summarizes business drivers, financial profile, and market behavior. The company is positioned within Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Current metrics include P/B of 3.73. Inovio Pharmaceuticals has a market cap of 115.42 M, ROE of -3.28%.
Methodology
Unless otherwise specified, financial data for Inovio Pharmaceuticals is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Inovio (USA Stocks:INO) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Inovio Pharmaceuticals may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Michael Smolkin - Member of Macroaxis Board of DirectorsInovio Pharmaceuticals Implied Volatility | 3.11 |
Inovio Pharmaceuticals' implied volatility exposes the market's sentiment of Inovio Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Inovio Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Inovio Pharmaceuticals stock will not fluctuate a lot when Inovio Pharmaceuticals' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Inovio Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Inovio Pharmaceuticals' short interest history, or implied volatility extrapolated from Inovio Pharmaceuticals options trading.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Momentum Invested few shares | |
 | Baby Boomer Prospects Invested over 20 shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Blockchain Invested few shares | |
 | Hedge Favorites Invested few shares | |
 | Disruptive Technologies Invested few shares | |
 | Data Storage Invested few shares | |
 | Investor Favorites Invested few shares | |
 | Software Invested few shares |
More Resources for Inovio Stock Analysis
A comprehensive view of Inovio Pharmaceuticals starts with financial statements and ratio context. Financial ratios provide context for profitability, efficiency, and growth trends. Outlined below are key reports that provide context for Inovio Pharmaceuticals Stock:Inovio Pharmaceuticals has a market cap of 115.42 M, operating margin of -492.03%, ROE of -3.28%. See Risk vs Return Analysis for portfolio-level analysis. This suggests a position in Inovio Pharmaceuticals within the portfolio mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. For a detailed overview of how to trade Inovio Stock, see our How to Trade Inovio Stock guide.Analysis related to Inovio Pharmaceuticals should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Holdings module to check your current holdings and cash position to determine if your portfolio needs rebalancing.
Earnings Share -2.72 | Revenue Per Share | Quarterly Revenue Growth 0.14 | Return On Assets | Return On Equity |
Understanding Inovio Pharmaceuticals includes distinguishing between market value and book value, where book value reflects Inovio's accounting equity. Inovio Pharmaceuticals' market capitalization is 115.42 M. With a P/B ratio of 3.73, the market values Inovio Pharmaceuticals well above its book equity. Enterprise value stands at 75.33 M. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
The concept of value for Inovio Pharmaceuticals differs from its quoted price, since each reflects a different lens. For Inovio Pharmaceuticals, key inputs include a P/B ratio of 3.73, ROE of -3.28%, and revenue of 217.76 K. Trading price represents the transaction level agreed by market participants.